By simultaneously inhibiting CDK4/6 and managing CDK2 activity, it may be possible to induce cell cycle arrest more effectively and prevent the proliferation of cancer cells that have adapted to evade conventional regulatory mechanisms. This evidence concerns the gene CDK4 and cancer.